Tag: msk

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient’s T cells so they recognize and attack cancer cells. These CAR (chimeric antigen receptor) T cells are then multiplied in a…

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient’s T cells so they recognize and attack cancer cells. These CAR (chimeric antigen receptor) T cells are then multiplied in a…

Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact…

Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690. doi.org/10.1016/j.cell.2014.09.050 (2014). Sherman, S. I. Thyroid carcinoma. Lancet 361, 501–511. doi.org/10.1016/s0140-6736(03)12488-9 (2003). Article  PubMed  Google Scholar  Tong, J. et al. Poorly differentiated thyroid carcinoma: a clinician’s perspective. Eur. Thyroid J. 11, doi.org/10.1530/ETJ-22-0021 (2022). Asioli, S….

Broaden your search Refine your search Sign up for job alerts Get new jobs for this search by email Found 1 job for $200,000 or more Position URL to apply: apply.interfolio.com/132461   The Cecil H. and…

$96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate…

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT, Actinium’s…

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. Article  PubMed  Google Scholar  Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al….

What You Should Know: Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the…

PRESS RELEASE Published September 19, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 19, 2023 USA News Group A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial Sloan…

Myriad Genetics is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad’s minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. The partners will be…

Pay Range $96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

Developmental biologist Eric Lai, PhD, and his lab at Memorial Sloan Kettering Cancer Center (MSK) have been studying hotbeds of biological conflict. Only instead of battles between outside invaders and internal defenders, they’ve uncovered an evolutionary battle of the sexes fought using a group of recently emerged genes. This conflict…

Skip to main contentThe Muse LogoA logo with &quat;the muse&quat; in dark blue text. All Filters Company Filters Company IndustryCompany SizePerks and BenefitsDiversity & Inclusion View 29 Results Bioinformatician Posted on Data Scientist / Bioinformatician, Biologics R&D Posted on mRNA – Bioinformatician Scientist – All Gender Posted on Senior Crop…

Research spearheaded by MSK unveiled a surprising connection between chromosomal instability and epigenetic changes, both of which are hallmarks of cancer — especially advanced, drug-resistant cancers. These defects work collectively, creating variations among individual cancer cells within the same tumor, thereby increasing their survival and resistance to treatment. The revelation…

SF3B1 MUT cells show selective sensitivity to PARP inhibitors To identify candidate therapeutic targets for cancers with SF3B1 hotspot mutations, we utilized the leukemia K562K700E (SF3B1K700E) and parental (SF3B1WT) isogenic cells1, to model one of the most prevalent SF3B1 hotspot mutations seen in patients8,19,20 (Fig. 1a,b and Supplementary Fig. 1a)….

Liquid biopsies have the potential to revolutionize cancer diagnosis and treatment decisions. Unlike biopsies that require removing tumor tissue, these tests use a simple blood draw to assess the molecular characteristics of cancer. Liquid biopsies can be done repeatedly and quickly, offering researchers a less invasive way to detect cancer…

Pay Range: $96,800.00-$154,900.00 Company Overview: The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

Details Posted: 23-Jul-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $96,800.00-$154,900.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages….

Skip to content Prog.World Prog.World Toggle Menu Share this: Facebook Reddit Pinterest Telegram WhatsApp Skype Post navigation Previous Previous Parsing a small application with jokes NextContinue How ChatGPT User Data Leaks Are Framing Users Similar Posts Online meetup of the MSK VUE.JS developer community Python – Dict You can’t just…

Hi all, I attempted to download a list of multi assay experiments using cBioDataPack a moment ago. after cbio <- cBioPortal() studies <- getStudies(cbio, buildReport = TRUE) PedPanCanStudyIds<-studies[grepl(‘Ped’, studies$name, ignore.case=TRUE) & grepl(‘Pan’, studies$name, ignore.case=TRUE), ]$studyId I ran PedPanCanMaeList<-list(); setwd(oD) PedPanCanMaeList[[PedPanCanStudyIds[1]]]<-cBioDataPack(PedPanCanStudyIds[1]); saveRDS(PedPanCanMaeList[[ PedPanCanStudyIds[1] ]], file=paste0(‘./cBioPortal/’, PedPanCanStudyIds[1], ‘.Rds’) ) PedPanCanMaeList[[PedPanCanStudyIds[2]]]<-cBioDataPack(PedPanCanStudyIds[2]); saveRDS(PedPanCanMaeList[[ PedPanCanStudyIds[2]…

BioNTech, Moderna, and CureVac are the three leading companies working on cancer vaccines based on personalized neoantigens. Even though the average population will know of BioNTech and Moderna for their COVID-19 work, the original business model was heavily centered around cancer therapies, which is what we will cover here. BioNTech…

Read the Full Video Transcript Sam Chang: Hello everyone, I’m Sam Chang. I’m a urologist at Vanderbilt University in Nashville, Tennessee and we’re quite fortunate to have a rising superstar in urologic oncology, Dr. Tim Clinton. Tim was a resident at UT Southwestern and finished his fellowship at Memorial Sloan…

(Adds Moderna’s comments on potential to seek accelerated approval in paragraphs 2-3, Phase 3 confirmatory study in paragraph 8) By Julie Steenhuysen CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread…

CHICAGO: Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the deadliest skin cancer would spread by 65 per cent over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. The results, presented at the American Society of…

[1/2] Signage is seen at the Merck & Co. headquarters in Kenilworth, New Jersey, U.S., November 13, 2021. REUTERS/Andrew Kelly/File Photo CHICAGO, June 5 (Reuters) – Adding an experimental mRNA-based vaccine from Moderna Inc (MRNA.O) and Merck & Co (MRK.N) reduced the risk that the most deadly skin cancer would…

NEW YORK — Cell-free DNA (cfDNA) derived from injured or dead cardiomyocytes is a promising biomarker to predict cancer therapy-related cardiac dysfunction (CTRCD) in HER2-positive breast cancer patients who undergo anthracycline chemotherapy, a new study has found. Previous studies have shown that anthracycline chemotherapy, which works by damaging cancer cell DNA, can…

Pay Range $78,900.00-$126,200.00 Company Overview The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across…

When the Sloan Kettering Institute opened its doors on Friday, April 16, 1948, an Associated Press wire story announced: “The world’s greatest cancer center opened here today.” And over the last seven and a half decades, institute researchers have made important contributions to the fundamental understanding of human biology, as well as…

PRESS RELEASE Published May 5, 2023 New Jersey, N.J, May. 05, 2023 (Digital Journal) Gene knockdown is a technique used in molecular biology to decrease the expression of a gene of interest. This can be accomplished using RNA interference (RNAi), a technique that uses short strands of RNA to specifically…

Earlier this year, the U.S. Food and Drug Administration (FDA) approved the drug elacestrant (Orserdu™) for certain people with advanced or metastatic breast cancer (stages 3 and 4). Elacestrant was effective in patients whose tumors were ER-positive, HER2-negative; had continued to grow after hormone therapy; and had a mutation (change)…

ORLANDO, Florida — Non-Hispanic persons of African ancestry typically have worse clinical outcomes from colorectal cancer (CRC) than individuals of other heritages, a disparity attributed to many factors, including socioeconomic, environmental, and genetic influences, as well as less access to care. Results from a new genomic study provide greater clarity…

By Jo CavalloPosted: 4/18/2023 10:44:00 AM Last Updated: 4/18/2023 12:19:55 PM Black individuals are disproportionately affected by colorectal cancer. They have the highest rates of the disease of any racial or ethnic group in the United States, and are about 20% more likely to develop colorectal cancer and about 40%…

Credit: CC0 Public Domain Genomic profiling of patients who were treated for colorectal cancer at a major U.S. cancer center showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry and were less likely to qualify for treatment with immunotherapy, according to data presented at…

Background: FBXW7 is recognized as a critical tumor suppressor gene and a component of the ubiquitin-proteasome system, mediating the degradation of multiple oncogenic proteins, including c-MYC, Cyclin E, c-Jun, Notch, p53. Around 16% of colorectal cancer (CRC) patients carried FBXW7 somatic mutations, while a comprehensive characterization of FBXW7 somatic mutations…

Details Posted: 12-Apr-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $116,800.00-$192,800.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery,…

Details Posted: 12-Apr-23 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Pay Range $116,800.00-$192,800.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation…

NEW YORK – Researchers from the Novartis Institutes for BioMedical Research (NIBR) have developed a method to determine clonal hematopoiesis in cancer patients from cell-free DNA (cfDNA) alone, using a computational model that can discriminate between blood-derived mutations arising from clonal hematopoiesis of indeterminate potential (CHIP) and tumor-derived mutations. CfDNA sequencing is gaining…

March 22, 2023 – As part of an international clinical trial, Miami Cancer Institute and Miami Neuroscience Institute, part of Baptist Health South Florida, have conducted the first low-intensity focused ultrasound (LIFU) aided liquid biopsy in the state of Florida in a patient with glioblastoma, most aggressive form of brain cancer….

March 22, 2023 10 min read Source/Disclosures Published by: Disclosures: Disis reports being a stockholder/founder of EpiThany; grants from Aston Sci. and Bavarian Nordic during the conduct of the breast cancer vaccine study; serving as editor of JAMA Oncology outside the submitted work; and royalties for a…

Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has announced a $123 million Series B financing. The financing was co-led by GordonMD Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management,…

Brown JS O’Carrigan B Jackson SP Yap TA Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2017; 7: 20-37 Farmer H McCabe N Lord CJ Tutt AN Johnson DA Richardson TB Santarosa M Dillon KJ Hickson I Knights C Martin NM Jackson SP Smith GC Ashworth A Targeting…

A phase 3 clinical trial (research study) of a targeted therapy called nirogacestat has found that the drug significantly shrank desmoid tumors in 41% of patients. Desmoid tumors (also known as aggressive fibromatosis) are a rare type of soft tissue tumor, and MSK has a team of doctors who are dedicated…

– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes –                   – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical…

CAR T cell therapy, often referred to as a “living drug,” has successfully treated blood cancers such as leukemia and lymphoma. The approach, which was pioneered at Memorial Sloan Kettering Cancer Center (MSK), involves equipping a person’s own immune cells (called T cells) with special receptors that can find cancer in…

– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes –                    – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage…

International Women’s Day takes place on March 8, which celebrates the achievements of women, and also shines a light on gender discrimination and the need to accelerate gender parity.  Although the percentage of women in the life sciences industry as a whole is almost equal to that of men, there…

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase…

Details Posted: 22-Feb-23 Location: New York, New York Salary: Open Categories: Operations Pay Range $63,700.00-$98,700.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery,…

Details Posted: 22-Jan-23 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Pay Range $63,700.00-$98,700.00 Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation…

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line. New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in addition to chimeric antigen receptor (CAR) T-cell therapy,…

MACHETE is a new CRISPR-based technique developed by researchers at the Sloan Kettering Institute (SKI) to study large-scale genetic deletions efficiently in laboratory models. People are already calling it the Machete Paper. Still, lead authors Francisco “Pancho” Barriga and Kaloyan Tsanov of the Sloan Kettering Institute don’t want the name…

Nationwide, Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes. We’re treating cancer, one patient at a time….

Cell-free DNA-based next-general sequencing (NGS) yielded low detection rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to an analysis published in JCO Precision Oncology. Researchers performed NGS of tumor DNA and plasma DNA using the MSK-IMPACT platform in 110 patients with metastatic ccRCC. They explored detection…

Details Posted: 05-Jul-22 Location: New York, New York Type: Full-time Salary: Open Categories: Academic/Faculty Company Overview At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re…

Accessibility and Equal Opportunity If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are…

December 14, 2021, NEW YORK, NY – A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) resulted in a…

Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 A study from Memorial Sloan Kettering Cancer Center (MSK) published today in the New England Journal of Medicine (NEJM), found that in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL) Polatuzumab vedotin with Rituximab, Cyclophosphamide, Doxorubicin,…

An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors…

At Memorial Sloan Kettering (MSK), we’re not only changing the way we treat cancer, but also the way the world thinks about it. By working together and pushing forward with innovation and discovery, we’re driving excellence and improving outcomes.  We’re treating cancer, one patient at a time. Join us and make a…

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…

If a disability prevents you from applying for a job through this website, click here. No other requests will be acknowledged. MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and…